In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 7 ( 2021-7-15), p. e0252048-
Abstract:
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved therapies for these tumors and their relentless progression results in high rates of morbidity and mortality. Through a combination of high throughput screens, preclinical in vivo modeling, and evaluation of the kinome en masse , we identified actionable drug targets and efficacious experimental therapeutics for the treatment of NF2 related schwannomas and meningiomas. These efforts identified brigatinib (ALUNBRIG ® ), an FDA-approved inhibitor of multiple tyrosine kinases including ALK, to be a potent inhibitor of tumor growth in established NF2 deficient xenograft meningiomas and a genetically engineered murine model of spontaneous NF2 schwannomas. Surprisingly, neither meningioma nor schwannoma cells express ALK. Instead, we demonstrate that brigatinib inhibited multiple tyrosine kinases, including EphA2, Fer and focal adhesion kinase 1 (FAK1). These data demonstrate the power of the de novo unbiased approach for drug discovery and represents a major step forward in the advancement of therapeutics for the treatment of NF2 related malignancies.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0252048
DOI:
10.1371/journal.pone.0252048.g001
DOI:
10.1371/journal.pone.0252048.g002
DOI:
10.1371/journal.pone.0252048.g003
DOI:
10.1371/journal.pone.0252048.g004
DOI:
10.1371/journal.pone.0252048.g005
DOI:
10.1371/journal.pone.0252048.g006
DOI:
10.1371/journal.pone.0252048.s001
DOI:
10.1371/journal.pone.0252048.s002
DOI:
10.1371/journal.pone.0252048.s003
DOI:
10.1371/journal.pone.0252048.s004
DOI:
10.1371/journal.pone.0252048.s005
DOI:
10.1371/journal.pone.0252048.s006
DOI:
10.1371/journal.pone.0252048.s007
DOI:
10.1371/journal.pone.0252048.s008
DOI:
10.1371/journal.pone.0252048.s009
DOI:
10.1371/journal.pone.0252048.s010
DOI:
10.1371/journal.pone.0252048.s011
DOI:
10.1371/journal.pone.0252048.s012
DOI:
10.1371/journal.pone.0252048.s013
DOI:
10.1371/journal.pone.0252048.s014
DOI:
10.1371/journal.pone.0252048.s015
DOI:
10.1371/journal.pone.0252048.s016
DOI:
10.1371/journal.pone.0252048.s017
DOI:
10.1371/journal.pone.0252048.s018
DOI:
10.1371/journal.pone.0252048.s019
DOI:
10.1371/journal.pone.0252048.s020
DOI:
10.1371/journal.pone.0252048.s021
DOI:
10.1371/journal.pone.0252048.s022
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Bookmarklink